Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03936478|
Recruitment Status : Suspended (Interim Analysis)
First Posted : May 3, 2019
Last Update Posted : April 27, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer DCIS LCIS||Radiation: MRIdian Radiation Treatment Unit||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This study will have a lead-in phase consisting of 10 patients, followed for 6-months from the date of completion of radiotherapy for the tenth patient. The second phase of accrual (20 patients) will commence only if three or fewer patients (3/10=30%) have CTCAE v 5.0 grade 3 or higher skin toxicity (radiation dermatitis) or Lövey et al. grade 3 or higher fat necrosis.|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)|
|Actual Study Start Date :||May 16, 2022|
|Estimated Primary Completion Date :||January 2027|
|Estimated Study Completion Date :||January 2031|
Experimental: 8.2 Gy Radiation Therapy
Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
Radiation: MRIdian Radiation Treatment Unit
partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
- Physician Reported Cosmesis: 1-year [ Time Frame: up to 1-year ]The Harvard Cosmesis Scale will be used to report cosmesis at 1 year post treatment. The physician will report how the breast looks relative to original appearance or untreated breast (excellent, good, fair, poor). The physician answers 9 questions on a scale of 0-2 where 0 is none, 1 is present but does not affect cosmesis, 2 is present and affects cosmesis. Scoring is objective with lower scores indicating improved conditions.
- Participant Quality of Life: BCTOS Survey [ Time Frame: up to 5 years ]Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales.The Breast Cancer Treatment Outcomes Scale (BCTOS) is a 22-item scale scored 1-4 where 1 is none, 2 is slight, 3 is moderate, and 4 is large. Total score ranges from 22-88 where lower scores indicated better outcomes.
- Participant Quality of Life: Convenience of Care Scale [ Time Frame: up to 5 years ]Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales. The Convenience of Care scale is an 8-item scale scored 0 (not at all) to 10 (a lot). The total score ranges from 0-80 where lower scores indicate less disruptive interventions.
- Participant Quality of Life: MOS SF-36 Survey [ Time Frame: up to 5 years ]Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales.The Medical Outcomes Study Short Form - 36 (MOS SF-36) Vitality scale measures how a participant has felt in the last 4 weeks. 4-items are scored from 1-5 where 1 is all of the time and 5 is none of the time. 4-items are scored from 0 (no pain) to 10 (pain as bad as you can imagine). Total score ranges from 4-60 where lower scores indicate increased vitality.
- Physician Reported Cosmesis: 3-year [ Time Frame: up to 3 years ]The Harvard Cosmesis Scale will be used to report cosmesis at 1 year post treatment. The physician will report how the breast looks relative to original appearance or untreated breast (excellent, good, fair, poor). The physician answers 9 questions on a scale of 0-2 where 0 is none, 1 is present but does not affect cosmesis, 2 is present and affects cosmesis. Scoring is objective with lower scores indicating improved conditions.
- Physician Evaluated Fat Necrosis [ Time Frame: up to 5 years ]Fat necrosis will be assessed prior to treatment, at 6 months post RT, at 12 months post RT, and yearly through 5 years, graded as follows: Grade 0 is no fat necrosis, Grade 1 is Asymptomatic fat necrosis (only radiologic and/or cytologic findings), Grade 2 is Symptomatic fat necrosis not requiring medication (palpable mass with or without mild pain), Grade 3 is Symptomatic fat necrosis requiring medication (palpable mass with significant pain), Grade 4 is Symptomatic fat necrosis requiring surgical intervention.
- Acute Radiation Toxicity [ Time Frame: up to 90 days from completion of radiation therapy ]The NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be used to identify the type and to grade the severity of acute toxicities. Acute toxicities will be scored from the start of radiation to 90 days after completion of radiotherapy and late toxicities will be scored > 90 days from completion of radiation therapy.
- Late Radiation Toxicity [ Time Frame: up to 5 years ]The NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be used to identify the type and to grade the severity of late toxicities.
- Ipsilateral Breast Tumor Recurrence (IBTR) [ Time Frame: up to 5 years ]Defined as evidence of invasive or in situ breast cancer (except LCIS) in the ipsilateral breast. Participants who develop clinical evidence of tumor recurrence in the remainder of the ipsilateral breast must have a biopsy of the suspicious lesion to confirm the diagnosis with documentation of the location.
- Ipsilateral Regional Nodal Recurrence [ Time Frame: up to 5 years ]Defined as the development of tumor in the ipsilateral internal mammary, ipsilateral supraclavicular, ipsilateral infraclavicular and/or ipsilateral axillary nodes, as well as the soft tissue of the ipsilateral axilla, after operation.
- Disease Free Survival (DFS) [ Time Frame: up to 5 years ]Disease free survival (DFS) defined as the time from start of radiation to the time of documented recurrent disease in the ipsilateral breast or regional nodes (supraclavicular, axillary or internal mammary) or distant sites (e.g. bone, liver, lung or brain).
- Overall Survival (OS) [ Time Frame: up to 5 years ]Overall survival (OS) defined as the time from start of radiation to death from any cause.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||40 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
For all participants
- Participants should have no contraindications to undergo MRI scan as part of radiotherapy planning and treatment.
- Lumpectomy cavity must be clearly visible on CT and MRI scan at radiotherapy simulation.
- Pregnancy test negative in women of child bearing potential (WOCBP).
- The participant must consent to be in the study and must have signed an approved consent form conforming with institutional guidelines.
- Participants with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior and are deemed by their physician to be at low risk for recurrence. Participants with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
For participants with Invasive Carcinoma
Age: >=50 years
- Margins: Negative by at least 2 mm
- T Stage: Tis or T1
Age: 40-49 years
- Margins: Negative by at least 2 mm
- T Stage: Tis or T1 OR
Age: >=50 years IF participant has at least 1 of the pathologic factors below and does not have any "unsuitable" factors (below)
- Size 2.1-3.0 cm (size of the invasive component)
- Close margins (<2 mm)
- Limited/focal Lymphovascular Space Invasion (LVSI)
- ER (-)
- Clinically unifocal with total size 2.1-3.0 cm (Microscopic multifocality allowed, provided the lesion is clinically unifocal (a single discrete lesion by physical examination and ultrasonography/mammography) and the total lesion size (including foci of multifocality and intervening normal breast parenchyma) falls between 2.1 and 3.0 cm).
- Invasive lobular histology
- Extensive Intraductal Component (EIC) <=3 cm
For participants with DCIS
Suitable Criteria, DCIS allowed if all of the following are met:
- Low to intermediate nuclear grade
- Size <=2.5 cm
- Resected with margins negative at >=3mm OR
- Pure DCIS <=3 cm if "suitable" criteria not fully met
Exclusion Criteria (unsuitable criteria) :
- Men are not eligible for this study.
- BRCA1/2 mutation positivity.
- Age < 40 years (American Society for Radiation Oncology (ASTRO) Unsuitable Criteria).
- Positive resection margins on post operative pathology(ASTRO Unsuitable Criteria).
- Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.
- Suspicious micro calcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign.
- Non-epithelial breast malignancies such as sarcoma or lymphoma.
- Proven multicentric carcinoma (invasive cancer or DCIS) (ASTRO Unsuitable Criteria).
- Pure DCIS >3 cm in size (ASTRO Unsuitable Criteria).
- Presence of extensive intraductal component >30mm (ASTRO Unsuitable Criteria).
- Paget's disease of the nipple.
- History of previous invasive breast cancer, DCIS, synchronous bilateral invasive or non-invasive breast cancer. (Participants with a history of LCIS treated by surgery alone are eligible.)
- Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation.
- Concurrent therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, Aromatase Inhibitors or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention or neoadjuvant therapy.
- Breast implants.
- Prior breast or thoracic radiotherapy for any condition or treatment plan that includes regional nodal irradiation.
- Collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma.
- Pregnancy or lactation at the time of treatment. Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy.
- Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the participant from meeting the study requirements.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03936478
|United States, Wisconsin|
|University of Wisconsin Carbone Cancer Center|
|Madison, Wisconsin, United States, 53705|
|Principal Investigator:||Bethany Anderson, MD||University of Wisconsin, Madison|
|Responsible Party:||University of Wisconsin, Madison|
|Other Study ID Numbers:||
2019-0322 ( Other Identifier: Institutional Review Board )
SMPH\HUMAN ONCO\HUMAN ONCO ( Other Identifier: UW Madison )
A533300 ( Other Identifier: UW Madison )
NCI-2019-03111 ( Registry Identifier: NCI Trial ID )
Protocol Version 5/10/2021 ( Other Identifier: UW Madison )
|First Posted:||May 3, 2019 Key Record Dates|
|Last Update Posted:||April 27, 2023|
|Last Verified:||April 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
Neoplasms by Site